Vermillion, Inc.  

(Public, NASDAQ:VRML)   Watch this stock  
Find more results for J. Fred Miller, III
2.06
-0.04 (-1.90%)
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.06 - 2.11
52 week 1.20 - 2.95
Open 2.10
Vol / Avg. 23,871.00/44,661.00
Mkt cap 88.82M
P/E     -
Div/yield     -
EPS -0.52
Shares 43.12M
Beta 1.61
Inst. own 28%
Aug 12, 2015
Q2 2015 Vermillion Inc Earnings Release (Estimated) Add to calendar
May 11, 2015
Q1 2015 Vermillion Inc Earnings Call
May 11, 2015
Q1 2015 Vermillion Inc Earnings Release
Mar 25, 2015
Q4 2014 Vermillion Inc Earnings Call - Webcast
Mar 25, 2015
Q4 2014 Vermillion Inc Earnings Release
Mar 9, 2015
Vermillion Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -435.02% -761.96%
Operating margin -448.16% -762.04%
EBITD margin - -756.45%
Return on average assets -77.45% -70.09%
Return on average equity -96.35% -83.48%
Employees 31 -
CDP Score - -

Address

Suite 100 12117 Bee Caves Road Building Three
AUSTIN, TX 78738
United States - Map
+1-512-5190400 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vermillion, Inc. is engaged in the discovery, development and commercialization of medical tests that help physicians diagnose, treat and improve outcomes for patients with gynecologic cancers and related diseases. The Company’s tests are intended to detect, characterize and stage disease, and to help guide decisions regarding prognosis and patient treatment. The Company’s lead product is OVA1, is an ovarian cancer test system that integrates a software algorithm and blood test. It addresses a clear unmet clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. OVA1 measures the levels of five proteins found in the blood and then uses software called OvaCalc to calculate a single score. A woman’s risk of cancer is measured by using a 0-10 scale versus predetermined cut-off points. Women who are pre-menopausal have a cut off of 5.0 whereas postmenopausal women have a 4.4 cutoff.

Officers and directors

James T LaFrance Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Valerie Barber Palmieri President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Donald G. Munroe Ph.D. Senior Vice President - Business Development, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Laura A. Miller Senior Vice President - Sales/Customer Experience
Age: 44
Bio & Compensation  - Reuters
Eric J. Schoen Chief Accounting Officer, Vice President - Finance
Age: 46
Bio & Compensation  - Reuters
Fred Ferrara Chief Information Officer
Age: 46
Bio & Compensation  - Reuters
Holly B. Bauzon Vice President - Sales and Managed Markets
Age: 47
Bio & Compensation  - Reuters
Peter S. Roddy Lead Independent Director
Age: 55
Bio & Compensation  - Reuters
Robert S. Goggin III Director
Age: 51
Bio & Compensation  - Reuters
James S. Burns Independent Director
Age: 68
Bio & Compensation  - Reuters